Compounds for the treatment of dementia related diseases

Details Compounds for the treatment of dementia related diseases Compounds for the treatment of dementia related diseases

2007-04-17

2007-04-17

Saeed, Kamal S. (Department: 1626)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C514S310000, C514S301000, C514S302000, C514S303000, C514S266200, C546S143000, C546S144000, C546S114000, C546S115000, C546S117000, C546S118000, C544S283000

Reexamination Certificate

active

10499217

ABSTRACT:
The present invention relates to new compounds of formula (I) wherein Y, P, R1, R2, R3, n, m are defined as in claim1, a process for their preparation and new intermediates used therein, pharmaceutical composition containing said therapeutically active compounds and to the use of said active compounds in therapy, especially in the prevention and/or treatment of dementia related disease, Alzheimer's Disease and conditions associated with glycogen synthase kinase-3

REFERENCES:
patent: 1136493 (2001-09-01), None
patent: WO-95/33750 (1995-12-01), None
patent: WO-97/42187 (1997-11-01), None
patent: WO-99/10349 (1999-03-01), None
patent: WO-00/10975 (2000-03-01), None
Bruni et al. “Enolizable Cyclic Ketones. I. Reaction with Activated Heteroaromatic N-oxides” Annali di Chemica (Rome, Italy) (1967) 57(6), pp. 688-697.
Piyasena Hewawasam et al., “Synthesis and Structure-Activity Relationships of 3-Arylosindoles: A new Class of Calcium-Dependent, Large Conductance Potassium (Maxi-K) Channel Openers with Neuroprotective Properties”. J. Med. Chem., vol. 45, 2002, pp. 1487-1499.
Imahori and Uchida., Physiology and Pathology of Tau Protein Kinases in Relation to Alzheimer's Disease. J. Biochem. vol. 121, 1997, pp. 179-188.
Hoshi et al., “Regulation of mitochondrial pyruvate dehydrogenase activity by tau protein kinase I/glycogen synthase kinase 3β in brain”, PNAS vol. 93, Apr. 1996, pp. 2719-2723.
Bhat et al., “Regulation and localization of tyrosine216phosphorylation of glycogen synthase kinase-3β in cellular and animal models of neuronal degeneration”, PNAS vol. 97, No. 20, Sep. 2000, pp. 11074-11079.
Stambolic et al., “Lithium inhibits glycogen synthase kinase-3 activity and mimics wingless signalling in intact cells”, Current Biol. 1996, vol. 6, pp. 1664-1668.
Klein and Melton, “A molecular mechanism for the effect of lithium on development”, Proc. Natl. Acad. Sci. USA, vol. 93, Aug. 1996, pp. 8455-8459.
Kozlovaky et al., “Low GSK-3β Immunoreactivity in Postmortem Frontal Cortex of Schizophrenic Patients”, Am. J. Psychiatry vol. 157(5), May 2000, pp. 831-833.
Cotter et al., Abnormalities of Wnt signalling in schizophrenia-evidence for neurodevelopmental abnormality, NeuroReport, vol. 9, May 1998, pp. 1379-1383.
Nikoulina et al., “Potential role of glycogen synthase kinase-3 in skeletal muscle insulin resistance if type 2 diabetes”, Diabetes, vol. 49, Feb. 2000, pp. 263-271.
Gat et al., “De Novo Hair Follicle Morphogenesis and Hair Tumors in Mice Expressing a Truncated β-Catenin in Skin”, Cell, vol. 95, Nov. 1998, pp. 605-614.
Vijajaraghavan et al., “Role for Phosphorylation of Glycogen Synthase Kinase-3α in Bovine Sperm Motility Regulation”, Biol. Reprod., vol. 62(6) Jun. 2000, pp. 1647-1654.

Affiliated with

Also associated with

Rating

Compounds for the treatment of dementia related diseases does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Compounds for the treatment of dementia related diseases, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds for the treatment of dementia related diseases will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3783089